Patient Name : Miss.
LALVULMAWI Collected : 16/Apr/2025 09:03AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 10:45AM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 11:49AM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method
COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA
HAEMOGLOBIN 13.0 g/dL 12.5-15 Spectrophotometer
PCV 38.10 % 36-46 Electronic pulse &
Calculation
RBC COUNT 4.59 Million/cu.mm 3.8-4.8 Electrical Impedence
MCV 83 fL 83-101 Calculated
MCH 28.2 pg 27-32 Calculated
MCHC 34 g/dL 31.5-34.5 Calculated
R.D.W 16.3 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 6,500 cells/cu.mm 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 60.4 % 40-80 Flow cytometry
LYMPHOCYTES 29.4 % 20-40 Flow cytometry
EOSINOPHILS 2.2 % 1-6 Flow cytometry
MONOCYTES 8 % 2-10 Flow cytometry
BASOPHILS 0 % 0-2 Flow cytometry
CORRECTED TLC 6,500 Cells/cu.mm Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 3926 Cells/cu.mm 2000-7000 Calculated
LYMPHOCYTES 1911 Cells/cu.mm 1000-3000 Calculated
EOSINOPHILS 143 Cells/cu.mm 20-500 Calculated
MONOCYTES 520 Cells/cu.mm 200-1000 Calculated
Neutrophil lymphocyte ratio (NLR) 2.05 0.78- 3.53 Calculated
PLATELET COUNT 283000 cells/cu.mm 150000-410000 Electrical impedence
MPV 9 Fl 8.1-13.9 Calculated
Page 1 of 8
SIN No:BED250032915
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:03AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 10:45AM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 11:49AM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method
ESR , WHOLE BLOOD EDTA 10 mm at 1 hour 0-15 Modified Westergren
Page 2 of 8
SIN No:BED250032915
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:02AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 10:46AM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 12:20PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
LIVER FUNCTION TEST (LFT) WITH GGT , SERUM
BILIRUBIN, TOTAL 0.50 mg/dl 0-1.2 NBD
BILIRUBIN CONJUGATED (DIRECT) 0.24 mg/dl 0-0.2 Diazotized sulfanilic
acid
BILIRUBIN (INDIRECT) 0.26 mg/dL 0.0-1.1 Calculated
ALANINE AMINOTRANSFERASE 15.18 U/I 0-45 IFCC
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 22.5 U/I 0-31 IFCC
(AST/SGOT)
AST (SGOT) / ALT (SGPT) RATIO (DE 1.5 <1.15 Calculated
RITIS)
ALKALINE PHOSPHATASE 86.65 U/I 42-98 IFCC (AMP buffer)
PROTEIN, TOTAL 7.50 g/dl 6.4-8.3 Biuret
ALBUMIN 4.36 g/dl 3.5-5.2 Bromcresol Green
GLOBULIN 3.14 g/dL 2.0-3.5 Calculated
A/G RATIO 1.39 0.9-2.0 Calculated
GAMMA GLUTAMYL 9.78 U/I 0-55 IFCC
TRANSPEPTIDASE (GGT)
Comment:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis
(Albumin) Common patterns seen:
1. Hepatocellular Injury: *AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT – Elevated levels indicate hepatocellular
damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST:
ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons’s diseases, Cirrhosis,
but the increase is usually not >2.Note- If both SGPT and SGOT are within reference range then AST:ALT (De Ritis ratio) does not have any clinical significance.
2. Cholestatic Pattern:*ALP – Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin (Direct) and GGT
elevated- helps to establish hepatic origin.
3. Synthetic function impairment:*Albumin- Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
4. Associated tests for assessment of liver fibrosis - Fibrosis-4 and APRI Index.
Page 3 of 8
SIN No:SE04896151
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:03AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 12:35PM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 01:55PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
IRON STUDIES (IRON + TIBC) , SERUM
IRON 35.2 µg/dL 60-180 TPTZ
TOTAL IRON BINDING CAPACITY 386.9 µg/dL 261-462 Calculated
(TIBC)
UNSATURATED IRON BINDING 351.70 µg/dL 155-355 NITROSO-PSAP
CAPACITY (UIBC)
% OF SATURATION 9.1 % 14-50 Calculated
Comment:
Transferrin is the primary plasma iron transport protein, which binds iron strongly at physiological pH. Transferrin is generally only
25% to 30% saturated with iron. The additional amount of iron that can be bound is the unsaturated iron-binding capacity (UIBC).
Diurnal variation is seen in serum iron levels—normal values in midmorning, low values in midafternoon, very low values
(approximately 10 μg/dL) near midnight.
TIBC measures the blood’s capacity to bind iron with transferrin (TRF). Estrogens and oral contraceptives increase TIBC levels.
Asparaginase, chloramphenicol, corticotropin, cortisone, and testosterone decrease the TIBC levels.
% saturation represents the amount of iron-binding sites that are occupied. Iron saturation is a better index of iron stores than
serum iron alone. % saturation is decreased in iron deficiency anemia (usually <10% in established deficiency).
Page 4 of 8
SIN No:SE04896152
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:02AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 12:36PM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 02:23PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM
TRI-IODOTHYRONINE (T3, TOTAL) 121 ng/dL 84.6-202 ECLIA
THYROXINE (T4, TOTAL) 8.42 µg/dL 5.12-14.06 ECLIA
TSH (Ultrasensitive/4thGen) 2.130 µIU/mL 0.270-4.20 ECLIA
Comment:
For Pregnant Women Bio Ref Range for TSH in µIU/mL
First trimester 0.33 – 4.59
Second trimester 0.35 – 4.10
Third trimester 0.21 – 3.15
1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its
prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of
normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive
hormone. Only a very small fraction of circulating hormone is free and biologically active.
4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication &
circulating antibodies.
TSH T3 T4 FT4 Conditions
Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune
High Low Low Low
Thyroiditis
Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone
High N N N
Treatment.
N/Low Low Low Low Secondary and Tertiary Hypothyroidism
Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early
Low High High High
Pregnancy
Low N N N Subclinical Hyperthyroidism
Low Low Low Low Central Hypothyroidism, Treatment with Hyperthyroidism
Low N High High Thyroiditis, Interfering Antibodies
N/Low High N N T3 Thyrotoxicosis, Non thyroidal causes
High High High High Pituitary Adenoma; TSHoma/Thyrotropinoma
Page 5 of 8
SIN No:SPL25014081
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:02AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 12:36PM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 02:23PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF IMMUNOLOGY
Page 6 of 8
SIN No:SPL25014081
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:02AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 12:36PM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 02:36PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
VITAMIN D (25 - OH VITAMIN D) , 11.2 ng/mL 30-100 ECLIA
SERUM
Comment:
BIOLOGICAL REFERENCE RANGES
VITAMIN D STATUS VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY <10
INSUFFICIENCY 10 – 30
SUFFICIENCY 30 – 100
TOXICITY >100
The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is
the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency
can also cause osteomalacia, which frequently affects elderly patients.
Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of
which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as
well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.
Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D,
which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin
D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval
of greater than 30 ng/mL is a target value established by the Endocrine Society.
Decreased Levels:- Inadequate exposure to sunlight, Dietary deficiency, Vitamin D malabsorption, Severe Hepatocellular
disease., Drugs like Anticonvulsants, Nephrotic syndrome.
Increased levels:- Vitamin D intoxication.
Page 7 of 8
SIN No:SPL25014081
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:03AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 12:36PM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 01:55PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
DEPARTMENT OF IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
VITAMIN B12 , SERUM 392 pg/mL 197-771 ECLIA
Comment:
Population based data reflecting exact scenario of vitamin B12 levels in Indian population is still evolving, however, different studies
reporting a deficiency in adults, pregnant women and children ranging from 16% to 77% with average of about 47%. This high
incidence is attributed to vegetarian food habits of large majority of Indian population.
Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss
of proprioception, poor coordination, and affective behavioral changes. A significant increase in RBC MCV may be an important
indicator of vitamin B12 deficiency. B12 levels in the range of 150 to 190 pg/ml may not be associated with any clinical
manifestations, while B12 levels below 100 pg/ml are often associated with clinical symptoms. However, for an individual based on
other co-morbid conditions or other nutritional deficiency (especially folate) the manifestations can vary accordingly.
If clinical symptoms suggest deficiency, measurement of active vitamin B12, MMA and homocysteine should be considered as
further workup.
Test Name Result Unit Bio. Ref. Interval Method
FERRITIN , SERUM 4.8 ng/mL 11.0-306.8 CLIA
Comment:
Ferritin estimation is useful in the diagnosis of iron deficiency anemia and iron overload.
Increased levels seen in hemachromatosis, frequent blood transfusions with packed RBCs and alcoholic liver disease.
Decreased levels seen in heavy menstrual bleeding, poor absorption of iron, iron deficiency anaemia and long term GI bleed.
Ferritin is an acute phase reactant and thus may be increased with inflammation, chronic infection, liver disease, auto-
immune disorders and some type of cancers. Ferritin is not used to detect or monitor these conditions.
*** End Of Report ***
Page 8 of 8
SIN No:SPL25014082
Patient Name : Miss.LALVULMAWI Collected : 16/Apr/2025 09:03AM
Age/Gender : 26 Y 11 M 21 D/F Received : 16/Apr/2025 12:36PM
UHID/MR No : SKAR.0000107839 Reported : 16/Apr/2025 01:55PM
Visit ID : SKAROPV141905 Status : Final Report
Ref Doctor : Dr.Dr. ALISHER SUBEY DEEN KHAN
TERMS AND CONDITIONS GOVERNING THIS REPORT
1. Reported results are for information and interpretation of the referring doctor or such other medical professionals,
who understandreporting units, reference ranges and limitation of technologies.Laboratories not be responsible for any
interpretation whatsoever.
2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the
verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies.
5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.
SIN No:SPL25014082
